EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+10.75%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$888M
AUM Growth
+$138M
Cap. Flow
-$23.2M
Cap. Flow %
-2.62%
Top 10 Hldgs %
78.6%
Holding
52
New
13
Increased
8
Reduced
4
Closed
22
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
0.6 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$28.5M
2
MGNX icon
MacroGenics
MGNX
+$21.3M
3
IMDZ
Immune Design Corp.
IMDZ
+$19.4M
4
ARRY icon
Array Biopharma Inc
ARRY
+$18.6M
5
APLS icon
Apellis Pharmaceuticals
APLS
+$16.8M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$40M
2
MRNS icon
Marinus Pharmaceuticals, Inc
MRNS
+$21.3M
3
FBRX icon
Forte Biosciences
FBRX
+$18.7M
4
CTMX icon
CytomX Therapeutics
CTMX
+$15.1M
5
INDP icon
Indaptus Therapeutics
INDP
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 83.97%
2 Miscellaneous 16.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MDGL icon
26
Madrigal Pharmaceuticals
MDGL
$10.7B
$3.21M 0.36%
+35,000
New +$2M
2017 Q4
0 quarters
DNLI icon
27
Denali Therapeutics
DNLI
$2.85B
$3.13M 0.35%
+200,000
New +$3.59M
2017 Q4
0 quarters
XNCR icon
28
Xencor
XNCR
$1.78B
$2.48M 0.28%
112,976
+22,862
+25% +$496K
2017 Q3
1 quarter
MRTX
29
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.88M 0.21%
+103,240
New +$1.6M
2017 Q4
0 quarters
NTLA icon
30
CALL
Intellia Therapeutics
NTLA
$1.6B
$1.44M 0.16%
+75,000
New +$1.73M
2017 Q4
0 quarters
ACRS icon
31
Aclaris Therapeutics
ACRS
$500M
– –
-60,000
Closed -$1.55M –
ADVM icon
32
DELISTED
Adverum Biotechnologies
ADVM
– –
-76,295
Closed -$2.79M –
BMY icon
33
Bristol-Myers Squibb
BMY
$121B
– –
-17,060
Closed -$1.09M –
CTMX icon
34
CytomX Therapeutics
CTMX
$490M
– –
-829,771
Closed -$15.1M –
FATE icon
35
Fate Therapeutics
FATE
$230M
– –
-2,262,678
Closed -$8.96M –
FBRX icon
36
DELISTED
Forte Biosciences
FBRX
– –
-4,006
Closed -$18.7M –
INDP icon
37
Indaptus Therapeutics
INDP
$298M
– –
-670
Closed -$13.4M –
INSM icon
38
Insmed
INSM
$21.2B
– –
-405,400
Closed -$12.7M –
OMER icon
39
Omeros
OMER
$1.37B
– –
-450,000
Closed -$9.73M –
RGLS icon
40
DELISTED
Regulus Therapeutics
RGLS
– –
-43,660
Closed -$6.55M –
SGMO icon
41
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-222,388
Closed -$3.34M –
TPST icon
42
Tempest Therapeutics
TPST
$11M
– –
-1,201
Closed -$4.99M –
VRTX icon
43
CALL
Vertex Pharmaceuticals
VRTX
$126B
– –
-67,600
Closed -$10.3M –
ZLAB icon
44
Zai Lab
ZLAB
$2.55B
– –
-159,535
Closed -$4.31M –
SYRS icon
45
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-10,400
Closed -$1.53M –
DCPH icon
46
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-45,000
Closed -$855K –
MRNS icon
47
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-905,568
Closed -$21.3M –
SGEN
48
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-30,000
Closed -$1.63M –
FSTX
49
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-4,000
Closed -$269K –
CLVS
50
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-25,765
Closed -$2.12M –
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2017 Portfolio in Review

As of Q4 2017, EcoR1 Capital held 52 positions worth $888M, up 18% from $750M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

EcoR1 Capital's Q4 2017 filing shows 13 new, 8 increased, 4 reduced and 22 closed positions. Its largest new stake was MacroGenics: 1,140,794 shares worth $21.7M. The largest sale was Immunomedics Inc, an estimated $40M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 97% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q4 2017 buy was MacroGenics: 1,140,794 shares worth $21.7M.
  • EcoR1 Capital added most to Dicerna Pharmaceuticals, Inc. in Q4 2017, an estimated $28.5M increase.
  • EcoR1 Capital's biggest Q4 2017 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $12.3M.
  • EcoR1 Capital fully exited Immunomedics Inc in Q4 2017, selling an estimated $40M.
  • EcoR1 Capital's ten largest holdings make up 79% of its $888M portfolio in Q4 2017.
  • EcoR1 Capital opened 13 new positions and closed 22 in Q4 2017.
  • EcoR1 Capital's portfolio value rose 18% quarter-over-quarter to $888M.

Based on EcoR1 Capital's 13F filing for Q4 2017, filed 14 Feb 2018.